Article citationsMore>>

Crizotinib, A.A.C.R. Yielded a High Objective Response Rate for Adult Patients with ALK-Positive Inflammatory Myofibroblastic Tumor.
https://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1173#.Wy4cXKdKiUk

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top